Patheon Overview
Pro stress-test →Patheon operates as a Global CDMO providing integrated drug development, clinical trials, and manufacturing services. Acquired by Thermo Fisher Scientific, Patheon is one of the industry's most widely recognized contract development and manufacturing organizations (CDMOs) with more than 60 locations worldwide.
Strategic Profile
Pro stress-test →The company offers comprehensive contract development and manufacturing organization (CDMO) and contract research organization (CRO) solutions to accelerate drug development journeys. Their capabilities span small and large molecules, advanced therapies like viral vectors, cell therapy, and mRNA, and steriles. Patheon delivers complete end-to-end CDMO capabilities for small molecules, large molecules, advanced therapies, clinical trials, and commercial services to help move from molecule to medicine to market.
Competitive Landscape
Pro stress-test →Patheon's top competitors include companies like Anthem Biosciences, KBI Biopharma and Abingdon Health. Patheon competes in the CDMO market as a diversified, integrated provider with capabilities across small molecules, biologics, and advanced therapies. Its scale (60+ global facilities, 8,400+ staff) and Thermo Fisher backing differentiate it from mid-sized competitors.
Industry Context
Patheon operates in Contract Development and Manufacturing Organizations (CDMO).
Key facts
Founded: 1974 · Headquarters: Durham, North Carolina, US · Employees: 8,400+ · Revenue: $1.9B (2016 pre-acquisition) · Market cap: N/A